Results from a Phase 3, Multicenter, Noninferiority Study of Ravulizumab (ALXN1210) versus Eculizumab (ECU) in Adult Patients (pts) with Paroxysmal Nocturnal Hemoglubinuria (PNH) Naive to Complement Inhibitors (CI)